
Maximilian Stahl
@maxstahlmd
Director Leukemia Program @Yale @YaleCancer @SmilowCancer
Prior @DanaFarber @harvardmed @MSKCancerCenter @TradIMYale
ID: 1372629451218038792
18-03-2021 19:22:25
155 Tweet
784 Followers
290 Following

One of the most brilliant, curious, and compassionate young physicians I have ever known is applying for #IMresidency this year #Match2025 🤩. I am super excited for you Nurefsan Sariipek, MD ! I wish you all the best of luck, our future oncologist 🥺



Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations. Maximilian Stahl Dana-Farber #leusm #oncology onclive.com/view/menin-inh…

🎉 Out now! 🎉 Amer Zeidan MBBS,MHS عامر زيدان (Yale Cancer Center), Harry Erba (Duke Health), Courtney DiNardo (MD Anderson Cancer Center), and Maximilian Stahl (Dana-Farber) come together for this #ASH24 roundtable to discuss precision medicine in #AML. 📺 Watch here! buff.ly/4iZR2j4


Menin inhibitors such as revumenib could address unmet needs in the treatment of patients with relapsed/refractory AML harboring KMT2A rearrangements or NPM1 mutations. Maximilian Stahl Dana-Farber #leusm #oncology onclive.com/view/menin-inh…


Join us TODAY at 6PM CET 📌Post #ASH24 Webinar Dedicated to AML Register for FREE bit.ly/4h4a4TQ Maximilian Stahl Mohamad Mohty

📢 We are LIVE! Post #ASH24 Webinar Dedicated to AML 🔗 Register for FREE: bit.ly/4h4a4TQ Maximilian Stahl Mohamad Mohty


📽️Now on demand! Our latest IACH Post #ASH24 webinar Dedicated to AML with Maximilian Stahl Watch the full webinar for FREE👇 iach.org/post-congress-… Maximilian Stahl Mohamad Mohty

Would like to thank Dr. Richard Stone for his remarkable guidance and my friend and Collegue Maximilian Stahl

Don't miss our #ASH24 roundtables! Experts in #MDS, #MPN, and #AML discuss the latest updates and treatment options. ➡️ buff.ly/485jWYt Prithviraj Bose Andrew Kuykendall MD Lucia Masarova, MD Amer Zeidan MBBS,MHS عامر زيدان Maximilian Stahl Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Andrew Brunner Abdulraheem Yacoub Tiffany Tanaka Keith W Pratz MD


⭐️ AML Pathways of treatment AJH 2025 AML Update on Diagnosis and Management - Frontline and Relapse by Shai Shimony Maximilian Stahl



Our latest review explores the emerging role of Myeloid-Derived Suppressor Cells (MDSCs) in AML & MDS, GVHD modulation & therapeutic targeting. Big thanks to my amazing mentors Jan Bewersdorf, Maximilian Stahl & Amer Zeidan MBBS,MHS عامر زيدان 🙏 📖 doi.org/10.1080/147371… #AML #MDS #ImmunoOncology


Bitter sweet goodbye on my last day Dana-Farber. I was lucky to have the best colleagues and so many patients who have inspired me! My fav impression from DFCI: The beams of the clinic building has the names of patients quite literally forming the foundation of everything we do!


“7 + 3” in AML may soon be history. Maximilian Stahl predicts a major shift toward #TargetedTherapies—like the menin inhibitor #Revumenib—for newly diagnosed #AML. bit.ly/4iPPZS7 #Hematology #Oncology #LeukemiaCare Dana-Farber

Excited to join the team Yale Cancer Center and Smilow Cancer Hospital as the Director of the Leukemia Program. Yale University has been my home away from home ever since I came here as a medical student many years ago. medicine.yale.edu/news-article/h…

